Gabriela Tomescu
Corporate Officer/Principal bei Apneon, Inc.
Aktive Positionen von Gabriela Tomescu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Apneon, Inc.
Apneon, Inc. Medical SpecialtiesHealth Technology Founded in 2003 by Dr. Lionel Nelson and Eric Doelling, Apneon is dedicated to developing innovative solutions for treating obstructive sleep apnea (OSA) - the cessation of breathing during sleep. OSA is a serious and life-threatening condition that plagues millions of Americans and is most commonly recognized by excessive daytime sleepiness. Even with current treatments, sleep apnea is associated with significantly increased risk of stroke and death. Current treatment methods tend to be poorly tolerated, and/or of limited efficacy. Apneon is developing a unique and inventive approach intended to provide an effective treatment for OSA. | Corporate Officer/Principal | 01.09.2005 | - |
Karriereverlauf von Gabriela Tomescu
Ausbildung von Gabriela Tomescu
The Ohio State University | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Graduate Degree |
Georgetown University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Graduate Degree | 2 |
Undergraduate Degree | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Apneon, Inc.
Apneon, Inc. Medical SpecialtiesHealth Technology Founded in 2003 by Dr. Lionel Nelson and Eric Doelling, Apneon is dedicated to developing innovative solutions for treating obstructive sleep apnea (OSA) - the cessation of breathing during sleep. OSA is a serious and life-threatening condition that plagues millions of Americans and is most commonly recognized by excessive daytime sleepiness. Even with current treatments, sleep apnea is associated with significantly increased risk of stroke and death. Current treatment methods tend to be poorly tolerated, and/or of limited efficacy. Apneon is developing a unique and inventive approach intended to provide an effective treatment for OSA. | Health Technology |
- Börse
- Insiders
- Gabriela Tomescu
- Erfahrung